tilization of 5HTT gene polymorphism as a prognostic indicator in cancer
Not Applicable
Recruiting
- Conditions
- cancer. We are recruiting patients with a known primary cancer of the following types: lymphoma, lung, gastrointestinal tumours, genitourinary tumours, hepatocellular cancer, breast, nasopharyngeal cancers). Adjustment for cancer type in the statisticall analysis will be done by including cancer type in the regression model.Cancer - Other cancer types
- Registration Number
- ACTRN12610000028000
- Lead Sponsor
- niversity of Alexandria
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Over 16 years of age
-Have a known primary cancer
-Able and willing to give consent
-Life expectancy more than 6 months
For study 2, an additional criterion will be added: the possession of at least one short allele of the 5HTT gene.
Exclusion Criteria
Patients are considered ineligible if they have overt psychopathology or mental impairment at enrollment into the study, or if they are enrolled in other behavioural or psychosocial studies
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to progression will be the primary endpoint, where progression is defined as one or more of the following: death attributable to cancer, appearance of new lesions, unequivocal increase in size of existing lesions, persistent elevation in levels of tumour markers. Decline in performance status or increase in tumour-related symptoms are not going to be accepted as indicators of progression unless supported by objective evidence of tumour progression obtained by radiological and/or laboratory assessment.[baseline, 6 months, 1 year and 2 year follow up points]
- Secondary Outcome Measures
Name Time Method